A Phase 1 interventional study of Reference Formulation (R) and LY3337641 (T1) in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-17.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purposes of this study are to determine:
The study has four periods. Individuals will participate in all four periods. Each period will include 4 overnight stays (5 days) in the Clinical Research Unit (CRU).
This study is expected to last up to 8 weeks. This includes the initial screening period, the study or dosing period, and the follow up period.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A single, PO dose of reference formulation (R) given orally with water after an overnight fast in one of four periods.
Drug: Reference Formulation (R)
A single, PO dose of LY3337641(20mg) test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.
Drug: LY3337641 (T1)
A single, PO dose of LY3337641 (20mg) test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.
Drug: LY3337641 (T1)
A single, PO dose of LY3337641 (20 mg) test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.
Drug: LY3337641 (T2)
Administered PO
20 mg PO
20 mg PO
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641
Time frame: Period 1,2,3,4 (Day 1): Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48 and 72 hours postdose
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3337641
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of LY3337641
Time frame: Period 1,2,3,4 (Day 1): Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48 and 72 hours postdose
4 period, 4 sequence, randomized crossover study with at least 5 days between doses.
| Milestone | Sequence ADBC | Sequence BACD | Sequence CBDA | Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 8 |
| Received at least 1 dose of study drug | 7 | 7 | 7 | 8 |
| Completed | 7 | 7 | 7 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence ADBC | Sequence BACD | Sequence CBDA | Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 7 | 7 | 8 |
| Completed | 7 | 6 | 7 | 8 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Scheduling conflict | 0 | 1 | 0 | 0 |
| Milestone | Sequence ADBC | Sequence BACD | Sequence CBDA | Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 8 |
| Completed | 7 | 6 | 7 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence ADBC | Sequence BACD | Sequence CBDA | Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 6 | 7 | 8 |
| Completed | 7 | 5 | 7 | 8 |
| Not completed | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 0 |
| Milestone | Sequence ADBC | Sequence BACD | Sequence CBDA | Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 5 | 7 | 8 |
| Completed | 7 | 5 | 7 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence ADBC | Sequence BACD | Sequence CBDA | Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 5 | 7 | 8 |
| Completed | 7 | 5 | 7 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
| Milestone | Sequence ADBC | Sequence BACD | Sequence CBDA | Sequence DCAB |
|---|---|---|---|---|
| Started | 7 | 5 | 7 | 8 |
| Completed | 7 | 5 | 7 | 8 |
| Not completed | 0 | 0 | 0 | 0 |
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641
| nanograms per milliliter (ng/mL) | Reference Formulation (R-fasted) | LY3337641 (T1-fasted) | LY3337641 (T1-fed) | LY3337641 (T2-fasted) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641 | 66.7 ± 40 | 64.9 ± 41 | 56.8 ± 44 | 65.5 ± 35 |
Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of LY3337641
| nanograms*hour per milliliter (ng*h/mL) | Reference Formulation (R-fasted) | LY3337641 (T1-fasted) | LY3337641 (T1-fed) | LY3337641 (T2-fasted) |
|---|---|---|---|---|
| Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3337641 | 373 ± 44 | 371 ± 47 | 351 ± 42 | 361 ± 43 |
Collected over 2 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Reference Formulation (R-fasted) | 0/28 (0%) | 0/28 (0%) | 6/28 (21.4%) |
| LY3337641 (T1-fasted) | 0/29 (0%) | 0/29 (0%) | 4/29 (13.8%) |
| LY3337641 (T1-fed) | 0/27 (0%) | 0/27 (0%) | 5/27 (18.5%) |
| LY3337641 (T2-fasted) | 0/27 (0%) | 0/27 (0%) | 2/27 (7.4%) |
| Event | Reference Formulation (R-fasted) | LY3337641 (T1-fasted) | LY3337641 (T1-fed) | LY3337641 (T2-fasted) |
|---|---|---|---|---|
| Catheter site bruiseGeneral disorders | 1/28 | 1/29 | 3/27 | 0/27 |
| Catheter site swellingGeneral disorders | 1/28 | 2/29 | 2/27 | 1/27 |
| HeadacheNervous system disorders | 2/28 | 0/29 | 0/27 | 0/27 |
| ErythemaSkin and subcutaneous tissue disorders | 2/28 | 0/29 | 0/27 | 0/27 |
| Catheter site erythemaGeneral disorders | 1/28 | 2/29 | 1/27 | 1/27 |
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 38 ± 7.6 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 1 |
| Male | 28 |
| Ethnicity (NIH/OMB)(Participants) | Overall |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 29 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 29 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 0 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| Singapore | 29 |
| Body Mass Index (BMI)(kilograms per meter squared) | Overall |
|---|---|
| Mean | 25.53 ± 2.69 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2017 to primary completion in May 2017, 1 month.
Results were first posted in Oct 2023, 6 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poseltinib